The Institut Jules Bordet is a renowned multidisciplinary center dedicated to the fight against cancer, integrating clinical care, research, and teaching. Located in Brussels, Belgium, it is the only accredited OECI-designated comprehensive cancer center in the country.

Mission and Approach

The Institut Jules Bordet provides a truly multidisciplinary approach to cancer diagnosis and therapy. Treatment decisions are made collaboratively by specialist doctors and healthcare professionals, including oncologists, surgeons, and radiotherapists. The institute employs the latest techniques and technologies to ensure the highest standards of care.

Research Integration

A key feature of the institute is the close integration of research with medical practice. This allows patients to participate in clinical studies and benefit from the latest therapeutic advancements. The institute conducts numerous research programs in collaboration with other cancer centers and international networks, emphasizing innovation in cancer treatment.

Teaching Excellence

The Institut Jules Bordet is also known for its quality teaching. It is affiliated with the Université Libre de Bruxelles (ULB), and each year, it trains dozens of medical students and doctors in specialist courses, ensuring the next generation of healthcare professionals is well-prepared.

New Facility

In November 2021, the institute moved to a new state-of-the-art building on the ULB campus in Anderlecht. This facility spans 80,000 m², featuring advanced medical technology and dedicated spaces for research and patient care. It offers 250 hospital beds, including 172 single rooms, and 43 beds for day hospitalizations.

Specialized Services

1. Medical Oncology:

   • Comprehensive cancer treatment plans using chemotherapy, immunotherapy, targeted therapy, and hormone therapy.
   • Personalized treatment strategies based on the genetic profile of tumors.

2. Radiation Oncology:

   • Advanced radiotherapy techniques such as intensity-modulated radiotherapy (IMRT), image-guided radiotherapy (IGRT), and stereotactic body radiotherapy (SBRT).
   • Brachytherapy for specific types of cancer.

3. Surgical Oncology:

   • Minimally invasive and robotic-assisted surgeries.
   • Specialized surgeries for various types of cancers including breast, thoracic, gastrointestinal, and gynecological cancers.

4. Hematology:

   • Treatment and research in blood cancers such as leukemia, lymphoma, and multiple myeloma.
   • Bone marrow and stem cell transplantation.

5. Breast Cancer Center:

   • Dedicated unit for the diagnosis, treatment, and follow-up of breast cancer.
   • Multidisciplinary team approach for personalized care.

6. Oncogenetics:

   • Genetic counseling and testing for hereditary cancer syndromes.
   • Personalized prevention and surveillance programs for high-risk individuals.

7. Psycho-Oncology:

   • Psychological support and counseling for patients and their families.
   • Programs to help patients cope with the emotional and mental impact of cancer diagnosis and treatment.

The Institut Jules Bordet is renowned for its high-quality care, particularly in the field of oncology. The institute is a part of the Hôpital Universitaire de Bruxelles (H.U.B), ensuring comprehensive and multidisciplinary care. It is accredited by the Organisation of European Cancer Institutes (OECI) as a "Comprehensive Cancer Center," a designation that highlights its commitment to integrating research, training, and patient care​​.

The institute excels in several areas:

1. Multidisciplinary Approach: The Institut Jules Bordet employs a multidisciplinary approach to cancer treatment, involving specialists from various fields such as oncology, surgery, and radiotherapy. This ensures that patients receive well-rounded and expert care​​.

2. Innovative Research and Clinical Trials: The institute is heavily involved in clinical research and trials, which allow patients access to cutting-edge treatments and diagnostic techniques. Their research activities are supported by national and international collaborations, contributing to advancements in cancer care​.

3. Patient Satisfaction: The institute maintains a high patient satisfaction rate, with 93.7% of patients expressing satisfaction with their experience. This is a testament to the quality of care and the supportive environment provided to patients​​.

4. Remote Monitoring: The institute has implemented innovative remote monitoring solutions, such as the Resilience program, to improve follow-up care for cancer patients. This program helps reduce treatment-related toxicities and hospitalizations, enhancing patients' quality of life and overall treatment outcomes​.

Strategic Direction:

1. Comprehensive Cancer Care:

   • Providing holistic and patient-centered care for cancer patients, covering all aspects of diagnosis, treatment, and follow-up.
   • Ensuring multidisciplinary approaches to treatment, combining the expertise of oncologists, surgeons, radiologists, and other specialists.

2. Innovative Research:

   • Conducting pioneering research in cancer biology, treatment, and prevention.
   • Promoting translational research to quickly apply laboratory findings to clinical settings, improving patient outcomes.
   • Collaborating with international research institutions and participating in global clinical trials.

3. Education and Training:

   • Offering advanced education and training programs for medical professionals, researchers, and students in oncology.
   • Organizing seminars, workshops, and conferences to disseminate the latest knowledge and advancements in cancer treatment and research.

Purpose:

1. Excellence in Cancer Care:
   • To provide the highest quality of care to cancer patients, ensuring their physical, emotional, and psychological well-being.
2. Advancing Cancer Research:
   • To lead in innovative cancer research, contributing to the global fight against cancer through new discoveries and improved treatments.
3. Educating Future Leaders:
   • To train and inspire the next generation of oncology professionals, ensuring the continued advancement of cancer treatment and care.

The Institut Jules Bordet has received several prestigious awards and recognitions, highlighting its excellence in cancer treatment, research, and care.

1. OECI Accreditation: The institute has been twice accredited and certified by the Organisation of European Cancer Institutes (OECI) as a "Comprehensive Cancer Centre." This quality label is awarded only to multidisciplinary cancer care institutions that integrate research, training, and patient care while meeting certain quantitative criteria. The Jules Bordet Institute is unique in Belgium for holding this accreditation​​.

2. Silver Dolphin Award: The institute’s video, "Chronos & Kairos," produced in cooperation with Sunfishing Creations, won the Silver Dolphin at the 10th Cannes Corporate Media & TV Awards in 2019. This award was given for the excellence in presenting their study and clinical research through media​.

3. Young Physician Award - Jean Klastersky: Named after Professor Jean Klastersky, this award encourages research into supportive care in oncology. The first award was given in December 2019 at the Cancer Toxicity Management Conference in Paris. It supports young doctors involved in cancer patient care and includes financial support and enrollment at the MASCC Congress​​.

4. Innovative Equipment and Technology: The institute boasts of having the first MRI-Linac 1.5 Tesla in Belgium, a state-of-the-art radiotherapy equipment combining the precision of MRI with the capabilities of a linear accelerator, enhancing the precision of cancer treatment​​.

These accolades reflect the institute's commitment to advancing cancer treatment through research, innovative technology, and comprehensive patient care.